Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294364 | 1.00 | PTPRB (0.40) | PTPRBCYP4A11CYP4F2TSHRADRB2 | |
| SCHEMBL8240083 | 0.94 | PTPRB (0.37) | PTPRBCYP4A11CYP4F2TSHRADRB2 | |
| SCHEMBL2490598 | 0.92 | PTPRB (0.46) | PTPRBCYP4A11CYP4F2TSHRMAPT | |
| SCHEMBL2160851 | 0.86 | CYP4A11 (0.48) | PTPRBCYP4A11CYP4F2TSHRTDP1 | |
| SCHEMBL8245053 | 0.85 | PTPRB (0.41) | PTPRBCYP4A11CYP4F2TSHRADRB2 | |
| SCHEMBL2294402 | 0.82 | PTPRB (0.40) | PTPRBCYP4A11CYP4F2TSHRADRB2 | |
| SCHEMBL2294163 | 0.82 | CYP4A11 (0.41) | PTPRBCYP4A11CYP4F2TSHRADRB2 | |
| SCHEMBL8158261 | 0.79 | CYP4F2 (0.48) | PTPRBCYP4A11CYP4F2L3MBTL1MAPT | |
| SCHEMBL2291678 | 0.76 | TSHR (0.39) | PTPRBCYP4A11CYP4F2TSHRTDP1 | |
| SCHEMBL2674860 | 0.75 | PTPRB (0.33) | PTPRBCYP4A11CYP4F2TSHRLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940769-B1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER IP GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-1940769-B1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER IP GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-1940811-B1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-1940811-B1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-8609727-B2 | Dicarboxylic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1940811-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940769-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940809-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045370-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045370-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045433-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045433-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045366-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045366-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | TNNI3, TNNT2, FABP3 | PTPRB 308/4885CYP4A11 831/4885CYP4F2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.